There are many cogent arguments for supporting bench-to-bedside—or translational—research. Taxpayers demand, and funding entities often require, that the money spent on research generates some application in the future, whether that be a drug, a therapy, or a medical device that ultimately benefits patients. But the path from the laboratory bench to the clinic is not always an easy one. Solid public–private partnerships can make this journey considerably easier as evidenced by the benefits of such collaborations that Australia has seen in recent years. In this supplement, we have gathered a unique collection of papers from Science Translation Medicine as well as invited articles that highlight some of the challenges inherent in bench-to-bedside research and provide helpful insights into possible paths to improve the chances for its success.